EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition.

doi:10.1038/s41388-025-03634-3

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition.

Oncogene - 1 Jan 2026

Wisniewski David J, Voeller Donna, Addissie Yonit A, Deshmukh Sachin Kumar, Wu Sharon, Lustberg Maryam B, Wangsa Darawalee, Wangsa Danny, Heselmeyer-Haddad Kerstin, Greer Yoshimi Endo, Sledge George W, Lipkowitz Stanley

Abstract excerpt

EGFR family receptor tyrosine kinase signaling is commonly dysregulated in cancer by amplification or activating mutations. Although studies have investigated dual EGFR/PI3K inhibition in breast cancer, they have not determined biomarkers which predict success. We present evidence of a patient subset with EGFR amplification and PI3Kinase pathway mutations in breast cancer which can be synergistically targeted by...

Read the complete abstract on PubMed

Topics

Humans
ErbB Receptors
Breast Neoplasms
Female
Animals
Mutation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Signal Transduction

Cell Line, Tumor

Mice

Phosphoinositide-3 Kinase Inhibitors

Gene Amplification

Phosphatidylinositol 3-Kinases

Xenograft Model Antitumor Assays

Protein Kinase Inhibitors

Drug Synergism

Apoptosis

Source

Open in PubMed Open full text

Identifiers

PMID: 41291067
DOI: 10.1038/s41388-025-03634-3
PMCID: PMC12714574

Genes

EGFR
MB

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition.PMID 41291067Read ↗

EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibitionSemantic proximity Read ↗

Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC.Semantic proximity Read ↗

Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.Semantic proximity Read ↗

Exploiting the PI3K/AKT pathway for cancer drug discovery.Semantic proximity Read ↗

PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.Semantic proximity Read ↗

Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cellsSemantic proximity Read ↗

ErbB receptors and signaling pathways in cancer.Semantic proximity Read ↗

In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC.Semantic proximity Read ↗

Cooperative oncogenic effect and cell signaling crosstalk of co‑occurring HER2 and mutant PIK3CA in mammary epithelial cells.Semantic proximity Read ↗

CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.Semantic proximity Read ↗

Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells.Semantic proximity Read ↗

Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.